Transcription Factor Levels after Forward Programming of Human Pluripotent Stem Cells with GATA1, FLI1, and TAL1 Determine Megakaryocyte versus Erythroid Cell Fate Decision.
View / Open Files
Authors
Dalby, Amanda
Ballester-Beltrán, Jose
Lincetto, Chiara
Mueller, Annett
Foad, Nicola
Evans, Amanda
Turro, Ernest
Tijssen, Marloes R
Publication Date
2018-12-11Journal Title
Stem Cell Reports
ISSN
2213-6711
Publisher
Elsevier BV
Volume
11
Issue
6
Pages
1462-1478
Language
eng
Type
Article
This Version
VoR
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Dalby, A., Ballester-Beltrán, J., Lincetto, C., Mueller, A., Foad, N., Evans, A., Baye, J., et al. (2018). Transcription Factor Levels after Forward Programming of Human Pluripotent Stem Cells with GATA1, FLI1, and TAL1 Determine Megakaryocyte versus Erythroid Cell Fate Decision.. Stem Cell Reports, 11 (6), 1462-1478. https://doi.org/10.1016/j.stemcr.2018.11.001
Abstract
The production of blood cells and their precursors from human pluripotent stem cells (hPSCs) in vitro has the potential to make a significant impact upon healthcare provision. We demonstrate that the forward programming of hPSCs through overexpression of GATA1, FLI1, and TAL1 leads to the production of a population of progenitors that can differentiate into megakaryocyte or erythroblasts. Using "rainbow" lentiviral vectors to quantify individual transgene expression in single cells, we demonstrate that the cell fate decision toward an erythroblast or megakaryocyte is dictated by the level of FLI1 expression and is independent of culture conditions. Early FLI1 expression is critical to confer proliferative potential to programmed cells while its subsequent silencing or maintenance dictates an erythroid or megakaryocytic fate, respectively. These committed progenitors subsequently expand and mature into megakaryocytes or erythroblasts in response to thrombopoietin or erythropoietin. Our results reveal molecular mechanisms underlying hPSC forward programming and novel opportunities for application to transfusion medicine.
Keywords
erythroblast, forward programming, lineage fate decision, megakaryocyte, pluripotent stem cells, Cell Differentiation, Cell Lineage, Cells, Cultured, Cytokines, Erythroid Cells, Erythropoietin, GATA1 Transcription Factor, Gene Silencing, Humans, Megakaryocytes, Pluripotent Stem Cells, Proto-Oncogene Protein c-fli-1, T-Cell Acute Lymphocytic Leukemia Protein 1, Thrombopoietin, Transgenes
Sponsorship
We acknowledge funding from the BHF Cambridge Centre of Excellence
(RE/13/6/30180), the Wellcome Trust (Novosang consortium) and the NHS Blood and Transplant Service
Funder references
Wellcome Trust (via Scottish National Blood Transfusion Service (SNTBS)) (XXL9126634)
Medical Research Council (MC_PC_12009)
British Heart Foundation (None)
MRC (MC_PC_14116 v2)
Identifiers
External DOI: https://doi.org/10.1016/j.stemcr.2018.11.001
This record's URL: https://www.repository.cam.ac.uk/handle/1810/287363
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk